Tocilizumab Clinical Trial Pipeline

S. No	Title	Location	References
1	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	Alessandria, Italy	https://clinicaltrials.gov/ct2/show/NCT04317092
2	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis	Chicago, Illinois, United States	https://clinicaltrials.gov/ct2/show/NCT04331795
3	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	Barcelona, Spain	https://clinicaltrials.gov/ct2/show/NCT04332094
4	Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection	New York, New York, United States	https://clinicaltrials.gov/ct2/show/NCT04377659
5	Efficacy of Early Administration of Tocilizumab in COVID-19 Patients	Alessandria, Italy	https://clinicaltrials.gov/ct2/show/NCT04346355
6	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia	United States	https://clinicaltrials.gov/ct2/show/NCT04372186
7	Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab	Zagreb, Croatia	https://clinicaltrials.gov/ct2/show/NCT04359667
8	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	L’Aquila, Italy	https://clinicaltrials.gov/ct2/show/NCT04332913
9	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia	California,United States	https://clinicaltrials.gov/ct2/show/NCT04320615
10	The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation	Israel	https://clinicaltrials.gov/ct2/show/NCT04377750
11	Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)	Switzerland	https://clinicaltrials.gov/ct2/show/NCT04335071
12	Tocilizumab Treatment in Patients With COVID-19	Mexico	https://clinicaltrials.gov/ct2/show/NCT04363853
13	Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019	China	https://clinicaltrials.gov/ct2/show/NCT04310228
14	Checkpoint Blockade in COVID-19 Pandemic	Spain	https://clinicaltrials.gov/ct2/show/NCT04335305
15	Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19	China	https://clinicaltrials.gov/ct2/show/NCT04306705
16	Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection	France	https://clinicaltrials.gov/ct2/show/NCT04333914
17	Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction	Greece	https://clinicaltrials.gov/ct2/show/NCT04339712
18	Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers	Brazil	https://clinicaltrials.gov/ct2/show/NCT04403685
19	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	United States	https://clinicaltrials.gov/ct2/show/NCT04361552
20	Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)	Russia	https://clinicaltrials.gov/ct2/show/NCT04380519
21	Treatment of COVID-19 Patients With Anti-interleukin Drugs	Belgium	https://clinicaltrials.gov/ct2/show/NCT04330638